Dr. Srinivas Murthy, professor in UBC’s pediatrics department, an infectious disease specialist at the B.C. Children’s Hospital and also the co-chair of the World Health Organization’s clinical research committee for the new coronavirus. poses in this undated handout photo. THE CANADIAN PRESS/HO, B.C. Children’s Hospital Research Institute

Dr. Srinivas Murthy, professor in UBC’s pediatrics department, an infectious disease specialist at the B.C. Children’s Hospital and also the co-chair of the World Health Organization’s clinical research committee for the new coronavirus. poses in this undated handout photo. THE CANADIAN PRESS/HO, B.C. Children’s Hospital Research Institute

Canadians at forefront of COVID-19 research as SARS outbreak informs response

Experts have learned a lot since severe acute respiratory syndrome, or SARS, first broke out in 2002

The potential for a worldwide pandemic has kept scientists in Canada at the ready and placed them at the forefront of the global response to the outbreak of the new coronavirus, several prominent researchers say.

Dr. Srinivas Murthy was among those experts who gathered at the World Health Organization’s headquarters in Geneva, Switzerland, last month to discuss how to combat the virus.

The outbreak of viruses with the potential to become pandemics is going to be “our new reality,” said Murthy, a professor at the University of British Columbia’s department of pediatrics and an infectious disease specialist at the B.C. Children’s Hospital.

“We just have to start getting used to this in some way (and) also be able to respond aggressively and effectively.”

Murthy is serving as co-chair of the WHO’s clinical research committee for the new virus, which is looking to establish better descriptions of COVID-19 including what causes it, who gets sick and why some individuals might become sicker.

The committee is also exploring how to help people recover from the novel coronavirus and establish how to determine whether a patient has recovered.

“I think if you were a betting person, you would say there is high risk of this continuing to spread in various parts of the world,” said Murthy, adding that it’s speculative to say how exactly it might progress.

The good news, he said, is that global collaboration has been expedited like never before, and experts have learned a lot since severe acute respiratory syndrome, or SARS, first broke out in 2002.

Canada was pivotal in describing SARS, largely because Ontario was hit hard by the virus, said Murthy, but at the time, research that would have helped the response to the outbreak was minimal. After SARS, researchers recognized that coronaviruses could be a problem in the future, said Murthy.

“We’ve learned quite a bit over the past 17 years.”

The Canadian Institute for Health Research — a funding body for health research in the country — has been “imperative” in helping to co-ordinate the global response to the new coronavirus as it relates to research priorities, such as the development of a preventative vaccine and therapeutic treatments, he said.

Charu Kaushic, the scientific director for the institute’s infection and immunity division, said the CIHR was able to put together a “rapid response” to COVID-19, making $6.75 million available for research into the new virus, a number she said will rise significantly when the total amount is announced in the coming days.

Kaushic agreed with Murthy that SARS was a catalyst for change in Canada.

“Since then, we’ve learned so many lessons,” said Kaushic, who also teaches in the department of pathology and molecular medicine at McMaster University in Hamilton. “We are much better prepared, both from a public health perspective, but also from a research perspective.”

Dr. Josef Penninger, who worked at Toronto’s Princess Margaret Hospital during the SARS outbreak, said he is ”totally amazed” at the speed with which scientists and some biotech companies have responded to COVID-19.

READ MORE: U.S. drugmaker readies possible coronavirus vaccine for testing

Penninger, the director of UBC’s Life Sciences Institute and Canada 150 chair in functional genetics, helped find the pathway through which SARS entered human cells and began to replicate — the protein ACE2 — which led to the development of a drug that could now help treat COVID-19.

“It turns out the new coronavirus uses exactly the same mechanism,” to enter cells, he said, adding that the drug, APN01, has already been tested on humans.

“We have ample data in humans already showing this protein we made is a therapy. It does exactly as we assumed it should do.”

But APN01 must still be tested in carefully controlled clinical trials before it is approved, he said.

Penninger is part of an international team working with Austrian biotech company Apeiron Biologics, which he co-founded, to conduct a pilot clinical trial in China involving 24 patients with severe cases of COVID-19.

READ MORE: ‘Very concerning’: Travellers from Iran asked to self-isolate as COVID-19 cases increase

The drug has arrived in China, he said, and the trial could start any day now. Half of the patients will receive the drug and half will receive a placebo with the results analyzed by an international panel of exerts, said Penninger, who hopes the drug will move quickly into a larger and definitive trial.

“It was all started in Canada,” Penninger said.

But multiple preventative and therapeutic treatments will be needed for the virus, which could be here to stay, he said.

“Hopefully it won’t, but there’s epidemiologists predicting this virus will stay with us and move around the globe like the flu in the future,” he added.

Matthias Gotte, chair of the medical microbiology and immunology department at the University of Alberta, has been working with his team to find out how another drug initially developed to treat Ebola might also work against coronaviruses.

American biotechnology company Gilead Sciences developed the drug remdesivir as a response to the Ebola epidemic in West Africa, where it was tested in a clinical trial, said Gotte.

Results showed that several other treatments were more effective against Ebola, but testing on monkeys infected with MERS — the Middle East respiratory syndrome-related coronavirus — suggested the drug could be effective against coronaviruses, explained Gotte.

The first patient diagnosed with COVID-19 in the United States received remdesivir for compassionate use, which allows the use of an unapproved drug to treat a seriously ill patient when no other treatments are available. The patient had been admitted to the intensive care unit and received the drug on the seventh day of illness, and the next day the patient showed a marked improvement and symptoms eventually disappeared altogether, Gotte said.

Last week, Gilead Sciences announced two clinical studies to evaluate the safety and efficacy of remdesivir in about 1,000 adults diagnosed with COVID-19. The company said the randomized studies will begin this month in countries across Asia and in other countries where COVID-19 has been diagnosed in higher numbers.

Gotte said no matter the results of the studies, his team will examine how the drug interacts with the new virus.

“Once we know how it works, we can make the drugs better.”

READ MORE: B.C. airline passenger lies about COVID-19 diagnosis in attempt to get flight changed

Brenna Owen, The Canadian Press


Like us on Facebook and follow us on Twitter.

CoronavirusJustin Trudeau

Get local stories you won't find anywhere else right to your inbox.
Sign up here

Just Posted

As of Friday, Alberta has under 10,000 active COVID-19 cases. (Image courtesy CDC)
Three new COVID-19 deaths in Central zone, Alberta under 10,000 active cases

The Central zone sits at 849 active cases, with 52 people in hospital and 10 in the ICU.

Black Press File Photo
Maskwacis RCMP lay charges for attempted murder, kidnapping, and flight from police

Female victim remains in hospital in serious condition.

(File photo)
After several years in limbo, Parkland Manor to be torn down

Rimoka Housing Foundation has received funding and approval for the demolition

Alberta’s chief medical officer of health Dr. Deena Hinshaw announced 16 additional deaths Thursday. (Photo by Chris Schwarz/Government of Alberta)
No easing of Alberta’s COVID-19 measures Thursday, 678 new COVID-19 cases

The province also hit 1,500 COVID-19 deaths since the beginning of the pandemic

Lucas Berg, left, with the backpacks filled with essential items he donated to the Red Deer Mustard Seed Jan. 19, 2021. (Photo submitted)
Ponoka youth fills backpacks for less fortunate

Lucas Berg, 14, of Ponoka County, donated 20 backpacks he filled with necessities

Alberta’s chief medical officer of health, Dr. Deena Hinshaw, updates media on the COVID-19 situation in Edmonton, Friday, March 20, 2020. Hinshaw says residents in long-term care and supportive living facilities will remain the priority as the province grapples with a looming slowdown in COVID-19 vaccine supply. THE CANADIAN PRESS/Jason Franson
Alberta long-term care residents remain priority in looming slowdown of COVID vaccine

There are 119 patients in intensive care and 1,463 people have died

In this Dec. 18, 2020 photo, pipes to be used for the Keystone XL pipeline are stored in a field near Dorchester, Neb.  THE CANADIAN PRESS/AP-Chris Machian /Omaha World-Herald via AP
‘Gut punch’: Alberta Premier Jason Kenney blasts Biden on revoked Keystone XL permit

Kenney said he was upset the U.S. wouldn’t consult with Canada first before acting

Joe Biden, then the U.S. vice-president, and Prime Minister Justin Trudeau take their seats at the start of the First Ministers and National Indigenous Leaders meeting in Ottawa, Friday, Dec. 9, 2016. THE CANADIAN PRESS/Adrian Wyld
Trudeau, Biden to talk today as death of Keystone XL reverberates in Canada

President Joe Biden opposed the Keystone XL expansion as vice-president under Barack Obama

Prince Edward Island’s provincial flag flies on a flag pole in Ottawa, Friday July 3, 2020. A lozenge plant in Prince Edward Island has laid off 30 workers, citing an “almost non-existent” cold and cough season amid COVID-19 restrictions. THE CANADIAN PRESS/Adrian Wyld
‘Almost non-existent’ cold and cough season: P.E.I. lozenge plant lays off 30 workers

The apparent drop in winter colds across the country seems to have weakened demand for medicine and natural remedies

Gov. Gen. Julie Payette takes the royal salute from the Guard of Honour as she makes her way deliver the the throne speech, Wednesday, September 23, 2020 in Ottawa. THE CANADIAN PRESS/Fred Chartrand
Gov. Gen. Julie Payette resigns, apologizes for ‘tensions’ at Rideau Hall

Payette, who is the Queen’s representative in Canada, has been the governor general since 2017

Grounded WestJet Boeing 737 Max aircraft are shown at the airline’s facilities in Calgary, Alta., Tuesday, May 7, 2019. WestJet will operate the first commercial Boeing 737 Max flight in Canada today since the aircraft was grounded in 2019 following two deadly crashes. THE CANADIAN PRESS/Jeff McIntosh
Passengers unfazed as WestJet returns Boeing 737 Max to service on Calgary flight

After a lengthy review process, Transport Canada cleared the plane to return to Canadian airspace

(Photo submitted)
Community Futures brings back Social Media Challenge for 2021

This time the challenge is for non-profits and community groups

A conveyor belt transports coal at the Westmoreland Coal Co.’s Sheerness mine near Hanna, Alta., on Tuesday, Dec. 13, 2016. Coal mining impacts are already occurring in Alberta’s Rocky Mountains even as debate intensifies over the industry’s presence in one of the province’s most beloved landscapes. THE CANADIAN PRESS/Jeff McIntosh
As Alberta debates coal mining, industry already affecting once-protected Rockies

UCP revoked a policy that had protected eastern slopes of the Rockies from open-pit coal mining since 1976

Most Read